0000000000744853

AUTHOR

Sandro Billeci

showing 2 related works from this author

Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single‐centre open‐label uncontrolled trial

2020

Phosphodiesterase-5 inhibitors are the first-line therapy for erectile dysfunction (ED) after radical prostatectomy (RP). This single-centre open-label uncontrolled study evaluated the efficacy and safety of the new sildenafil orodispersible film (ODF) in ED treatment after RP. Sildenafil 100 mg ODF was administered twice a week for 3 months to patients under 75 years of age, with a Framingham cardiovascular risk score < 20% and a pre-operative International Index of Erectile Function (IIEF)-5 score ≥ 17, who had undergone open RP between 2016 and 2018. Erectile function was assessed pre-operatively, post-operatively and after treatment through the IIEF-5 score, the Sexual Encounter Prof…

Malemedicine.medical_specialtyPercentileSildenafilUrologymedicine.medical_treatment030232 urology & nephrologyUrologyUncontrolled Studyprostatic neoplasmsSildenafil Citrate03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyErectile DysfunctiontherapeuticsHumansMedicineAdverse effectProstatectomy030219 obstetrics & reproductive medicineFramingham Risk Scorebusiness.industryProstatectomyPenile ErectionOrodispersible filmGeneral MedicinePhosphodiesterase 5 Inhibitorsmedicine.diseaseTreatment OutcomeErectile dysfunctionchemistrybusinessAndrologia
researchProduct

Prognostic role in common clinical practice of neutrophil-to-lymphocyte ratio in unselected bladder cancer

2020

Oncologymedicine.medical_specialtyNo parole chiaveBladder cancerbusiness.industryUrologylcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaselcsh:RC254-282Clinical PracticeInternal medicinemedicineNeutrophil to lymphocyte ratiobusinessEuropean Urology Open Science
researchProduct